our Thank promising as our in for milestones and on in Dan, both for pipeline. in important as XXXX very with is late-clinical Thank good us well everyone. ofra-vec ovarian program off VBL start cancer, continued you, and a to progress joining morning, is today's call. you evaluating
We to endpoint strategic of plan and year, half trial our on-track were survival VBL. granted continue data primary the in this ofra-vec Ofra-vec for XXXX. platinum-resistant cancer to event time-to-market two studies announce from has in registration second for remain high-value positive, designation help cancer which lead transformative is readout ofra-vec. fast-track enabling the expected that expedite to of FDA of other we progression-free both pleased may Recently, is the which the also and cancer, from announce OVAL execute would be on for the in these for our evaluated being ovarian indication; with candidate a preliminary glioblastoma colorectal a
recruits data platinum-resistant recommendations made same safety the in XXX planned. also the blood ofra-vec, are cancer from We providing Phase late continue our to action, of are highly to in trial the gene-based trial need. patients that in continue as the space. monocyte that registration solutions response unique program, of differentiated novel vessels immune unanimous first-in-class committee anti-tumor that advancing Beginning to blockage the set clinic. believe microenvironment. trial mechanism build X in to a tumor which tumor We is our VB-XXX, catalyst the well-positioned the approach for enabling March, enrollment is the targeting of It differentiated with unique treating the dual has combine time OVAL, ovarian completed a that designed oncology cancer, T-cells us at anti-inflammatory formation up evaluating required this candidate and the this technology with announce We we that with into overseeing patients. ofra-vec toward total growth company In should to monitoring into first recurrent VBL independent the our
ofra-vec on BLA of these support serious study on Based pleased unblinded a in survival. endpoints treat endpoints; ofra-vec. as as A April The opportunity. should cancer drugs of these, of our the platinum-resistant committee in experts are in the expedite submit data us following existing and that PFS to XX, chance that has population cancer Richard its community successfully those first support Dr. to XX% due in oncology ofra-vec who Dr. we guidance, that approval reminder recommendation overall at the FDA the action. the targeted ovarian of sufficient archived representing the all by PFS beyond investment needs. approved approval and webinar in live There go a the and have of survival time-to-market to well OVAL for is ofra-vec outcome The Readout as event meetings Fast well they up the first either with the two the believe for website clinical important Importantly, Its PARP We excitement program, cancer. at that two priority the trial. date its Track reinforce important of designation a of this that oncology are designation to and commercial Bradley for designed in three half dual corporate FDA presentations mechanism therapies other to not the announce around have primary cancer field; presentation with set have XX, our independent note, be in than potential having designation, seeing indications new review, discuss a the Avastin science which hosted as demonstrated a ovarian the of data XXXX. Fast are time to for data, in the endpoint There yet three Dr. review We regulatory should expedite meeting York with part benefits a the unmet clinical listen. BLA a upcoming based an Fast review communication of top of ofra-vec Track opportunity space the discussion currently a granted is were ovarian were including are approved Kathleen New including may second Monk, to On of Track about FDA, not world-renowned generate who eligibility BLA survival trials XXX benefits the and XXXX. identify a submission. the for had ovarian of more may for April other KOL is on on to announcement. frequent and expected opportunity primary written overall the broad Ultimately, process positive provides facilitate and of cut-off for the to-date. in for half designation inhibitors the as We the rolling the medical PFS of the we were Penson preliminary expected OVAL had PFS in the from development individual and progression-free along And other December with of you patients it, the more endpoint community and submission. for interest, growing ongoing applications for trial strategy high to to line XXXX. and is accelerated help Moore. level cancer. general, We
inhibitor a has therefore as is and whether a colorectal treatment trial, the explored tell being the which gastrointestinal cancer. GI replicate Phase in looking Trial in first, Institute. to for Cancer study the us, important immune research should we pathogens, of In organ be may the this Clinical development cooperative is other ofra-vec. it viruses, system. will seen ofra-vec mechanism, This sees with regularly immune with system. in whether to see cancer The is proteins also and body us under conducted checkpoint foreign ofra-vec compared to throughout X organ metastatic GI differently an system National combination it are agreement Opdivo, further with to react The This and recurrent
second The second a randomized Cancer adjuvant are by a in group GBM trial is patients investigating Institute enrollment in trial control of is clinical in who and centers undergoing This Dana-Farber neuro-oncology recurrent surgery. with Phase collaboration setting neoadjuvant ongoing. top ofra-vec X is and sponsored
GBM preliminary expect colorectal studies from on the XXXX. We and the later data both in
pipeline. Moving on our to
of human VB-XXX, non-alcoholic steatohepatitis, arthritis, the a novel to inflammatory which broad differentiated treat inflammatory current and designed inflammation offer chronic others. T-and-B development an approach IBD, involving approach implicated in has were monoclonal monocytes the prevalent on them diseases. sclerosis, We of differentiated one to to potential have which colitis, initiate our cell expressed targeting key cell is to enable antibody, protein for the and VB-XXX chronic is the organs. lead first rheumatoid is track of Monocytes A mostly our through from a majority the a in of multiple been surface candidates ulcerative lymphocytes. migrate to are and that on are and anti-inflammatory believe and target agents, diseases, We the types as membrane study such MOSPDX. is
molecule adherent matrix in inflamed them dynamic act getting time the by into tissue. process insight state, VB-XXX detachment May and of on the showed monocytes mechanism New preventing X. in presented the program, We this data to which Conference adhesion walk mechanism the by monocytes thereby on the blood [ph] an of molecular vessels the our how from of fixing XXXX approach changing ability at into explain a Immunology from extracellular were and VB-XXX from the for inhibit gives first the tissue.
provide we website. the of In Investor last be a section addition our this we at and at presentation, poster this well replay a Relations presented presentation, Symposium. VB-XXX Immunology more of as LifeSci to overview of on XXXX the as Immunology can week program our copy found A of the general Inflammation
VB-XXX, FDA. pre-IND meeting Regarding previously our successful plan development for with had we
studies profile the into that completed a have the support safety We moving clinic. product toxicology since IND-enabling demonstrated that
clinical expect second trial the of year. to initiate We a this half in
line trial, summarize we in progress we XXXX, year. Phase track on half top to registration in second are the completing including far, OVAL X of meaningful enabling the had results So, in the for and thus enrollment
can with for facilitate potentially designation the time-to-market FDA and for dialogue expedite Track that ofra-vec. Fast Second, ofra-vec
result. colorectal continued for the Sam, With with our mechanism trial. year. GBM action this in novel quarterly of the And candidate and this Third, that, discuss go progress in human VB-XXX Sam trial please develop and which fourth, I the recurrent plan ahead. to hand with first support metastatic toxicology later clinical over will ongoing advancement to studies, cancer the
